
|Articles|April 26, 2004
Series of studies explore safety and efficacy of anti-VEGF monoclonal antibody treatment for exudative AMD
Two Phase III studies are now underway evaluating ranibizumab (formerlyrhu Fab V2, Lucentis; Genentech) for the treatment of exudative age-relatedmacular degeneration (AMD). The studies are based on Phase I/II study results,demonstrating it is well tolerated and offers promising biological and clinicalactivity, said Jeffrey S. Heier, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
3
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
4
Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD
5





















